Safety Evaluation of Tarlatamab in SCLC: A Systematic Review and Meta-Analysis.
Safety data on tarlatamab for small cell lung cancer adds to evidence about this emerging therapeutic option.
This PubMed record reports a newly indexed biomedical study. The available metadata supports conservative classification as a meta-analysis.
What the study was
- Study design
- Meta-analysis
- Population
- Humans
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- JTO clinical and research reports
Why it surfaced
Meta-analysis; relevance and evidence were scored conservatively from the PubMed abstract.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.